Institute of Neurogenetics, University of Luebeck, Luebeck, Germany2Department of Neurogenetics, Kolling Medical Institute, Royal North Shore Hospital and University of Sydney, Sydney, Australia.
Institute of Neurogenetics, University of Luebeck, Luebeck, Germany.
JAMA Neurol. 2014 Apr;71(4):490-4. doi: 10.1001/jamaneurol.2013.4677.
Mutations in the GNAL gene have recently been shown to cause primary torsion dystonia. The GNAL-encoded protein (Gαolf) is important for dopamine D1 receptor function and odorant signal transduction. We sequenced all 12 exons of GNAL in 461 patients from Germany, Serbia, and Japan, including 318 patients with dystonia (190 with cervical dystonia), 51 with hyposmia and Parkinson disease, and 92 with tardive dyskinesia or acute dystonic reactions.
We identified the following two novel heterozygous putative mutations in GNAL: p.Gly213Ser in a German patient and p.Ala353Thr in a Japanese patient. These variants were predicted to be pathogenic in silico, were absent in ethnically matched control individuals, and impaired Gαolf coupling to D1 receptors in a bioluminescence energy transfer (BRET) assay. Two additional variants appeared to be benign because they behaved like wild-type samples in the BRET assay (p.Ala311Thr) or were detected in ethnically matched controls (p.Thr92Ala). Both patients with likely pathogenic mutations had craniocervical dystonia with onset in the fifth decade of life. No pathogenic mutations were detected in the patients with hyposmia and Parkinson disease, tardive dyskinesias, or acute dystonic reactions.
Mutations in GNAL can cause craniocervical dystonia in different ethnicities. The BRET assay may be a useful tool to support the pathogenicity of identified variants in the GNAL gene.
最近的研究表明,GNAL 基因突变会导致原发性扭转痉挛。GNAL 编码的蛋白(Gαolf)对多巴胺 D1 受体功能和气味信号转导很重要。我们对来自德国、塞尔维亚和日本的 461 名患者的所有 12 个 GNAL 外显子进行了测序,包括 318 名肌张力障碍患者(190 名颈肌张力障碍患者)、51 名嗅觉减退和帕金森病患者以及 92 名迟发性运动障碍或急性肌张力障碍反应患者。
我们在一名德国患者和一名日本患者中发现了以下两种新的杂合假定突变:GNAL 中的 p.Gly213Ser 和 p.Ala353Thr。这些变体在计算机预测中被认为是致病性的,在种族匹配的对照个体中不存在,并且在生物发光能量转移(BRET)测定中削弱了 Gαolf 与 D1 受体的偶联。另外两种变体似乎是良性的,因为它们在 BRET 测定中表现得像野生型样本(p.Ala311Thr)或在种族匹配的对照中检测到(p.Thr92Ala)。两名可能存在致病性突变的患者均患有颅颈肌张力障碍,发病于 50 多岁。在嗅觉减退和帕金森病、迟发性运动障碍或急性肌张力障碍反应患者中未检测到致病性突变。
GNAL 突变可导致不同种族的颅颈肌张力障碍。BRET 测定可能是支持 GNAL 基因中鉴定出的变体致病性的有用工具。